Local Thermal Ablation with Continuous EGFR Tyrosine Kinase Inhibitors for EGFR-Mutant Non-small Cell Lung Cancers that Developed Extra-Central Nervous System (CNS) Oligoprogressive Disease
- 30 January 2019
- journal article
- research article
- Published by Springer Science and Business Media LLC in CardioVascular and Interventional Radiology
- Vol. 42 (5), 693-699
- https://doi.org/10.1007/s00270-018-02153-x
Abstract
Most epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors (TKIs) experience oligoprogressive disease. Local ablation for isolated resistant sites continued with the original EGFR-TKI showed good efficacy in these patients. We conducted this multicenter retrospective study to investigate the potential benefit of thermal ablation in NSCLC patients that developed extra-central nervous system (CNS) oligoprogressive disease during TKI treatment.Keywords
Funding Information
- National Natural Science Foundation of China (81502610)
This publication has 34 references indexed in Scilit:
- Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase InhibitorsJournal of Thoracic Oncology, 2013
- Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung CancerJournal of Thoracic Oncology, 2012
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Complications of microwave and radiofrequency lung ablation: personal experience and review of the literatureLa radiologia medica, 2011
- Complications After 1000 Lung Radiofrequency Ablation Sessions in 420 Patients: A Single Center’s ExperiencesAmerican Journal of Roentgenology, 2011
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyThe Lancet Oncology, 2011
- Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer ModelingScience Translational Medicine, 2011
- Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M MutationClinical Cancer Research, 2011
- Percutaneous radiofrequency ablation of lung tumours: results in the mid-term?European Journal of Cardio-Thoracic Surgery, 2006
- Percutaneous Radiofrequency Ablation of Malignancies in the LungAmerican Journal of Roentgenology, 2000